Fertilix Supplements and Assisted Reproductive Technology
NCT ID: NCT02621125
Last Updated: 2017-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2016-02-29
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle
NCT04758260
Oxidative Stress In Semen And Male Infertility
NCT03464656
Effect of Natural Antioxidant Supplement on Sperm DNA Fragmentation
NCT03646825
Impact of A Nutritional Supplements' Combination (FERTILIS) on Male Infertility
NCT04193358
Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient.
NCT06718426
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fertilix
Fertilix supplementation
Fertilix
daily supplementation
Placebo
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fertilix
daily supplementation
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male is between 20-55 years of age seeking treatment for infertility with his partner at URA and who is a candidate for an IUI, IVF or IVF-ICSI (excluding donor egg) procedure.
* Female is between 20-42 years of age
* Female exhibits tubal patency on hydrosonogram or hysterosalpingogram (HSG)
* Female exhibits normal uterine cavity by hysteroscopy, hydrosonogram or hysterosalpingogram (HSG).
Exclusion Criteria
* Men who have been taking nutraceuticals, vitamins or other compounds known to have antioxidant activities within4 weeks of the study. No other supplements may be taken with Fertilix.
* Men who have hypersensitivity or an allergy to any of the ingredients in Fertilix®.
* Men who have been treated with a chemotherapeutic agent known to cause sterility, such as cyclophosphamide.
* Men who have taking anabolic steroids or testosterone replacement within 4 months of the study.
* Men currently being treated with a Ca++ channel blocker or other medical treatment known to adversely affect sperm production or function.
* Men with HIV, hepatitis B and C.
20 Years
55 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CellOxess LLC
INDUSTRY
University Reproductive Associates
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter McGovern, MD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Reproductive Associates
Hasbrouck Heights, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Fertilix
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.